SILVERARC CAPITAL MANAGEMENT, LLC

BOSTON, MA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 12, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$820.9M2026 Q3+ $33.5M options (notional, not included)
Positions70
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.52.0%

SILVERARC CAPITAL MANAGEMENT, LLC reported 70 positions worth $820.9M as of September 30, 2026 (13F filed November 12, 2026). Largest holding: KOD (8.3%). Biggest move: add CELC ($24.0M).

10 / 70 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 KODKodiak Sciences$71.1M8.32%750,170——+6.3%
▸ 2 CELCCelcuity$63.9M7.47%803,193——-23.8%
▸ 3 COGTCogent Biosciences$50.4M5.90%1,574,698——-10.8%
▸ 4 URGNUroGen Pharma$46.7M5.46%1,148,689——-30.8%
▸ 5 IMNMImmunome$45.0M5.27%2,092,715——-12.7%
▸ 6 GLUEMonte Rosa Therapeutics$37.1M4.35%3,112,773——-23.2%
▸ 7 SGMTSagimet Biosciences$37.0M4.33%3,745,990——+3.4%
▸ 8 ASNDAscendis Pharma A/S$34.7M4.06%152,175——+20.9%
▸ 9 RYTMRhythm Pharmaceuticals$33.2M3.88%348,317——+12.9%
▸ 10 BIIBBiogen$25.5M2.98%112,790——+11.4%

Pro Feature

The remaining 60 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does SILVERARC CAPITAL MANAGEMENT, LLC hold as of Q3 2026?

SILVERARC CAPITAL MANAGEMENT, LLC reported 70 positions worth $820.9M in its Q3 2026 13F filing. Largest positions: KOD (8.3%), CELC (7.5%), COGT (5.9%), URGN (5.5%) and IMNM (5.3%).

What did SILVERARC CAPITAL MANAGEMENT, LLC buy in Q3 2026?

New positions: CLDX, CELLDEX THERAPEUTICS INC NEW, RAINIER ACQUISITION CORP, YARW and ARCT (18 in all). Added to: CELC, GLUE, KOD, BIIB and COGT (29 in all).

What did SILVERARC CAPITAL MANAGEMENT, LLC sell in Q3 2026?

Reduced: SNDX, ELVN, DNTH, PRAX and ASND (20 in all). Sold out entirely: ARK ETF TR, VCYT, SYNDAX PHARMACEUTICALS INC, GH and TRVI (21 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.